Bayer Aktiengesellschaft

Bayer Healthcare Aktiengesellschaft

Merck Serono S. A.

Bayer Schering Pharma Ag

Bayer Pharmaceuticals Corporation

Santhera Pharmaceuticals (schweiz) Ag

Bayer Aktiengeselischaft

Bayer Healthcare LLC

Adverio Pharma Gmbh

Santhera Pharmaceuticals Ag

Achim Feurer

Johannes-Peter Stasch

Alexander Straub

Klaus Dembowsky

Elisabeth Perzborn

Elke Stahl

Frank Wunder

Dieter Lang

Cristina Alonso-Alija

Raimund Kast

Stefan Weigand

Thomas Jaetsch

Dietmar Flubacher

Joachim H&uuml;tter

Rudolf Schohe-Loop

Joachim Schuhmacher

Peter-Rudolf Seidel

Bernard Schmidt

Franz-Josef Van Der Staay

Dieter Arlt

Ulrich Abel

Ulrich Niew&ouml;hner

Andreas Goutopoulos

Meinolf Thiemann

Matthias Schwarz

Renate Sekul

Xuliang Jiang

Joachim Luithle

Rudy Schreiber

Hans-Georg Lerchen

Klaus Münter

Thomas Schenke

Dhanapalan Nagarathnam

Walter Hubsch

Jacques P Dumas

Erwin Bischoff

Joachim Mittendorf

Heike Heckroth

Joachim Hutter

Ulrich Niewohner

Hartmut Schirok

Marcus Bauser

Cyrille Lescop

Holia Hatoum-Mokdad

Andreas Von Sprecher

Stephen Boyer

Ulrich Graedler

Jane C Chisholm

William Bullock

Richard J Fanelli

Richard T McCarthy

Georg Terstappen

Chantal F&uuml;rstner

Holger Deppe

Kerstin Otte

Ulrich Grädler

Gerhard König

Stephan-Nicholas Wirtz

Samir Bennabi

Chantal Furstner

Cesare Mondadori

Santiago Figueroa Perez

Chunguang Wang

Fabrice Heitz

Gabriele Handke

Wolfgang Roben

Heimo Ehmke

Elizabeth Perzborn

Hans Pluempe

Jean Mark Gnoth

Inge Ott

Miroslav Terinek

Joachim H{umlaut Over (u)}tter

Holger Herzner

Günther Metz

Sonja Nordhoff

Michael Soeberdt

Barbara Hoffmann-Enger

Philipp Weyermann

Hervé Siendt

Christian Rummey

Marco Henneböhle

Jens Ergüden

Klaus Muenter

Michael Erb

Robert Dallmann

Nuri Gueven

Stephan Bulat

The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

3-arylamino pyridine derivatives

The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin-4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amytrophic lateral sclerosis (ALS), anxiety and depression.

Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists

The invention provides novel, substituted 3-arylamino pyridine compounds (I) pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds. 

The invention relates to heteroaryloxy-substituted phenylaminopyrimidines, to methods for the production thereof, and to the use of the same for producing medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular diseases. The inventive compounds inhibit Rho-Kinase.

Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors

The present invention relates to novel morpholine-bridged indazole derivatives having the formula 

Morpoline-bridged indazole derivatives

The present invention relates to novel 4-amino-substituted pyrimidine derivatives which stimulate soluble guanylate cyclase, to processes for the preparation thereof, and to the use thereof for producing medicaments, in particular medicaments for the treatment of central nervous system diseases.

4-amino-substituted pyrimidine derivatives

This invention relates to methods of treatment of cardiovascular disorders, thromboembolic disorders, inflammation, and disorders of the central nervous system using pyrazol pyridine derivatives of formula (I) wherein Ris a radical of the formula &#x2014;O&#x2014;SO&#x2014;Rin which Ris optionally substituted C-alkyl, optionally substituted C-cycloalkyl, or optionally substituted phenyl; Ris H, optionally substituted C-alkyl-CO&#x2014; or optionally substituted C-alkyl-SO&#x2014;; as well as salts, stereoisomers, tautomers, and hydrates thereof.

Methods of treating medical conditions using sulfonate-substituted pyrazolopyridine derivatives

This invention relates to methods for treating sexual dysfunction, by administering a compound of the formula wherein Ris H or a di-C-alkylaminocarbonyl radical, and Ris a radical of the formula &#x2014;O&#x2014;C(X)&#x2014;NRRwherein X is O or S. The compound may also be administered in combination with at least one organic nitrate or NO donor, or in combination with at least one compound which inhibits the breakdown of cyclic guanosine monophosphate (cGMP).

Medical uses of carbamate-substituted pyrazolo-pyridine derivatives

The present invention relates to compounds which stimulate soluble guanylate cyclase, to the preparation thereof and to the use thereof as medicaments, in particular as medicaments for the treatment of cardiovascular disorders and/or sexual dysfunction.

Carbamate-substituted pyrazolopyridines

This invention relates to compounds of the formula in which R, R, and Rare as defined in the claims, to a process for preparing such compounds, to pharmaceutical compositions containing such compounds, and to methods of using such compounds for treatment of hypertension and sexual dysfunction.

Sulfonamide-substituted pyrazolopyridine compounds

This invention relates to compounds of the formulawherein Ris H or a di-C-alkylaminocarbonyl raical, and Ris a radical of the formula &#x2014;O&#x2014;C(X)&#x2014;NRRwherein X is O or S. A process for preparing such compounds, pharmaceutical compositions containing them, and methods for using them in treatment of hypertension are also disclosed and claimed.

Carbamate-substituted pyrazolopyridine-derivatives

The present invention relates to novel 2,5-disubstituted pyrimidine derivatives which stimulate soluble guanylate cyclase, to processes for the preparation thereof, and to the use thereof for producing medicaments, in particular medicaments for the treatment of central nervous system diseases.

2,5-disubstituted pyrimidine derivatives

Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.

Rho-kinase inhibitors

Growing community of inventors

Wilhelmsfeld, Germany

Achim Feurer